Cytovance Expands Partnership with Nature Technology Corp.

Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), has formed a new agreement with Nature Technology Corporation (NTC) for use of NTC’s proprietary HyperGRO manufacturing platform. This announcement is on the heels of Cytovance launching its Keystone Expression System pDNA manufacturing licensing program.

“Our pDNA programs have greatly advanced due, in-part, to our use of NTC’s HyperGRO technology,” said Bin Zhang, chief executive officer, Cytovance Biologics. “We look forward to extending our collaborative work to benefit more clients with their gene therapy projects.”

Cytovance’s Keystone Expression System pDNA manufacturing platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high quality, high yield pDNA. Cytovance is highly experienced in pDNA manufacturing and offers three quality levels including R&D Grade, Cytograde and CGMP Grade depending on the needs of the client.

“NTC has worked with Cytovance through many successful projects,” said Deborah Moorad-Watts, chief executive officer, Nature Tech. “We are excited to support them and their clients with our HyperGRO platform and bring more qualified drug options to market.”